Semaglutide and Postmenopausal Bleeding

On 16 September 2026, JCEM Case Reports published an account of a 58-year-old postmenopausal woman who began bleeding six weeks after starting semaglutide for weight reduction, with the spotting appearing roughly ten days after her dose was raised to 0.5 mg weekly^[1]. Her hemoglobin fell from 12.9 to 10.8 g/dL over that stretch. The authors, led by Prasad and colleagues, call the case a diagnostic challenge because every routine explanation for postmenopausal bleeding, cancer, structural disease, hormone reactivation, came back clean.

What the case report found

The patient had reached menopause eight years earlier, at age 50, and had gone the entire time without bleeding. A transvaginal ultrasound showed a thin endometrium under 4 mm with no focal lesions, and an endometrial biopsy came back atrophic, with no hyperplasia or malignancy^[1]. Cervical cytology from six months earlier had also come back negative.

Her hormone panel matched stable menopause rather than any reactivation: FSH at 68.4 mIU/mL, LH at 34.8 mIU/mL, and estradiol suppressed at 3.5 pg/mL^[1]. TSH, prolactin, and a pregnancy test were all unremarkable, and coagulation studies plus a vaginal culture ruled out a bleeding disorder or infection.

The authors scored the case a 6 on the Naranjo Adverse Drug Reaction Probability Scale, the standard tool for estimating whether a drug caused a reaction^[1]. A 6 means "probable", not proven. The rating rests mainly on the tight timing between the dose increase and the bleeding, and on the bleeding stopping within five weeks of the patient discontinuing semaglutide.

A mechanism the authors propose, not one they confirmed

Semaglutide is a GLP-1 receptor agonist, a drug that mimics a gut hormone which slows digestion and reduces appetite, and the case authors' explanation reaches past that usual pharmacology into how the body makes estrogen after menopause. In postmenopausal women, most circulating estrogen comes from fat tissue, where an enzyme called aromatase converts other hormones into estrogen. The authors propose that losing fat quickly, this patient lost 7.8 kg, or 8.4% of her starting weight, over eight weeks^[1], could destabilize an endometrium that had adapted to a steady low-estrogen state, in a way they compare to the bleeding that follows progestogen withdrawal.

That mechanism stayed a hypothesis. The biopsy and hormone panel were drawn weeks after the bleeding started, once the patient had already stopped the drug, so they capture a settled, atrophic endometrium rather than whatever was happening at the moment the bleeding began. The authors say plainly that this timing gap keeps them from confirming a transient proliferative phase ever occurred^[1].

It may not be specific to semaglutide

The case report leans on two other pieces of evidence. A 2023 case published in Cureus describes a 44-year-old perimenopausal woman who developed vaginal bleeding one week after her second dose of dulaglutide, a different GLP-1 receptor agonist; her bleeding stopped once the drug was withdrawn^[4]. Separately, a 2026 pharmacovigilance analysis of FDA adverse-event reports from 2022 through 2025 compared gynecological hemorrhagic events across more than 100,000 female-specific reports for tirzepatide and semaglutide^[3]. The two drugs showed up at almost the same rate: 0.60% of tirzepatide reports and 0.62% of semaglutide reports, a reporting odds ratio of 0.97 that the analysis reads as no real difference between the two.

That pharmacovigilance analysis comes with its own caveat. Nearly 95% of the tirzepatide reports originated from consumers rather than clinicians, versus about half of the semaglutide reports^[3], a gap the study's author flags as a reason to read the comparison cautiously instead of as a clean head-to-head.

What this does not show

One case, even a well-documented one, does not establish that semaglutide causes bleeding in postmenopausal women generally. The evidence so far is a Naranjo score of "probable" in a single patient, one earlier case involving a different drug in the same class, and a reporting-rate comparison its own author calls preliminary. None of it is a controlled trial, and the large randomized programs behind semaglutide, including the STEP-1 trial that reported a mean 14.9% weight loss at 68 weeks^[2], were not designed to catch a signal this specific in this small a population.

What the case does not change is the baseline rule for any postmenopausal bleeding, on any medication. A 2018 systematic review and meta-analysis in JAMA Internal Medicine, pooling data from 129 separate studies, found that roughly 9% of postmenopausal women who present with bleeding turn out to have endometrial cancer^[5]. That number is the reason the case report's authors worked through a full malignancy workup before considering semaglutide as an explanation, and it is the reason anyone with postmenopausal bleeding needs the same evaluation, whether or not they take a GLP-1 drug.

What this means

If you are taking semaglutide and notice postmenopausal bleeding, the sequence that matters is the one this patient's clinicians followed: get evaluated first, and only then discuss with your prescriber whether the medication is a plausible contributor. Whether to continue or stop semaglutide is a decision for you and your clinician together, not something the current evidence settles on its own.

The bigger open question is whether this turns out to be specific to semaglutide or, as the case authors suggest, a broader GLP-1 class signal that has gone undescribed mainly because postmenopausal women are underrepresented in the trials that built the class's safety profile in the first place.